Sharon X Xie

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease
    Sharon X Xie
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    J Int Neuropsychol Soc 16:278-86. 2010
  2. pmc Building an integrated neurodegenerative disease database at an academic health center
    Sharon X Xie
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 7:e84-93. 2011
  3. pmc Neuropathologic substrates of Parkinson disease dementia
    David J Irwin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Morris K Udall Parkinson s Disease Center of Excellence, Institute on Aging, Philadelphia, PA, USA
    Ann Neurol 72:587-98. 2012
  4. pmc Clinical and pathological continuum of multisystem TDP-43 proteinopathies
    Felix Geser
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Arch Neurol 66:180-9. 2009
  5. pmc The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice
    Bin Zhang
    Center for Neurodegenerative Disease Research, Institute on Aging and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 32:3601-11. 2012
  6. pmc Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis
    David J Libon
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19129, USA
    Neuropsychology 23:337-46. 2009
  7. pmc Genetic influences on cognitive decline in Parkinson's disease
    James F Morley
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
    Mov Disord 27:512-8. 2012
  8. pmc CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, CNDR, University of Pennsylvania School of Medicine, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 124:23-35. 2012
  9. pmc Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
    Brain 135:170-80. 2012
  10. pmc Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias
    Mark Yarchoan
    3615 Chestnut Street, Philadelphia, PA 19104, USA
    Brain 135:3749-56. 2012

Detail Information

Publications63

  1. pmc Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease
    Sharon X Xie
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    J Int Neuropsychol Soc 16:278-86. 2010
    ..These data suggest the presence of specific longitudinal patterns of impairment for episodic and semantic memory in AD and FTLD patients suggesting that all forms of dementia do not necessarily converge into a single phenotype...
  2. pmc Building an integrated neurodegenerative disease database at an academic health center
    Sharon X Xie
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 7:e84-93. 2011
    ..These comparative studies rely on powerful database tools to quickly generate data sets that match diverse and complementary criteria set by them...
  3. pmc Neuropathologic substrates of Parkinson disease dementia
    David J Irwin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Morris K Udall Parkinson s Disease Center of Excellence, Institute on Aging, Philadelphia, PA, USA
    Ann Neurol 72:587-98. 2012
    ..A study was undertaken to examine the neuropathological substrates of cognitive dysfunction and dementia in Parkinson disease (PD)...
  4. pmc Clinical and pathological continuum of multisystem TDP-43 proteinopathies
    Felix Geser
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Arch Neurol 66:180-9. 2009
    ....
  5. pmc The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice
    Bin Zhang
    Center for Neurodegenerative Disease Research, Institute on Aging and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 32:3601-11. 2012
    ..These data reveal that brain-penetrant MT-stabilizing drugs hold promise for the treatment of AD and related tauopathies, and that EpoD could be a candidate for clinical testing...
  6. pmc Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis
    David J Libon
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19129, USA
    Neuropsychology 23:337-46. 2009
    ..These data indicate that distinct patterns of neuropsychological impairment are maintained longitudinally, reflecting the unique anatomic distribution of relative disease burden in AD and FTLD...
  7. pmc Genetic influences on cognitive decline in Parkinson's disease
    James F Morley
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
    Mov Disord 27:512-8. 2012
    ..Clinically, these results suggest that genotyping can provide information about the risk of future cognitive decline for PD patients...
  8. pmc CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, CNDR, University of Pennsylvania School of Medicine, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 124:23-35. 2012
    ....
  9. pmc Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
    Brain 135:170-80. 2012
    ..In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease...
  10. pmc Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias
    Mark Yarchoan
    3615 Chestnut Street, Philadelphia, PA 19104, USA
    Brain 135:3749-56. 2012
    ....
  11. pmc Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors
    Krupali Desai
    Department of Family Medicine and Community Health, University of Pennsylvania, 3400 Spruce Street, 2 Gates Building, Philadelphia, PA 19104, USA
    Support Care Cancer 21:43-51. 2013
    ....
  12. pmc Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis
    Johannes Brettschneider
    Center for Neurodegenerative Disease Research CNDR, University of Pennsylvania School of Medicine, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 123:395-407. 2012
    ..In contrast, AD pathology in ALS is primarily related to increasing age and associated with a poorer performance on the MMSE...
  13. doi request reprint Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis
    Felix Geser
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Alzheimer s Disease Core Center, Institute on Aging, Philadelphia, USA
    Arch Neurol 65:636-41. 2008
    ....
  14. pmc Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center
    Melissa Gartenberg Livney
    From the Penn Memory Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Am J Geriatr Psychiatry 19:430-9. 2011
    ....
  15. pmc Plasma apolipoprotein A1 as a biomarker for Parkinson disease
    Judy K Qiang
    Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
    Ann Neurol 74:119-27. 2013
    ..To identify plasma-based biomarkers for Parkinson disease (PD) risk...
  16. pmc Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies
    David J Irwin
    Centre for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Alzheimer s Disease Core Centre, Institute on Ageing, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Brain 135:807-18. 2012
    ..Thus, inhibiting tau acetylation could be a disease-modifying target for drug discovery target in tauopathies...
  17. pmc Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Ageing, Centre for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Brain 136:2697-706. 2013
    ....
  18. pmc Neurodegeneration across stages of cognitive decline in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3615 Chestnut St, Ste 330, Philadelphia, PA 19104, USA
    Arch Neurol 68:1562-8. 2011
    ..To assess regions and patterns of brain atrophy in patients with Parkinson disease (PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia-level cognitive deficits (PDD)...
  19. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
    ..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
  20. pmc Frequency and clinicopathological characteristics of presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with dementia
    Steven E Arnold
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Alzheimers Dis 33:1089-95. 2013
    ..Considered together with the increased prevalence and mortality of AD reported in Puerto Rico, these high rates may reflect hereditary risk concentrated in the island which warrants further study...
  21. pmc The Philadelphia Brief Assessment of Cognition (PBAC): a validated screening measure for dementia
    David J Libon
    Department of Neurology, Drexel University College of Medicine, 245 North 15th Street, Philadelphia, PA 19102, USA
    Clin Neuropsychol 25:1314-30. 2011
    ..The PBAC is a valid tool and able to assesses differential patterns neuropsychological/behavioral impairment in a broad range of neurodegenerative conditions...
  22. ncbi request reprint Symptom burden among cancer survivors: impact of age and comorbidity
    Jun J Mao
    Department of Family Medicine and Community Health, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    J Am Board Fam Med 20:434-43. 2007
    ....
  23. pmc The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders
    Sharon Ash
    University of Pennsylvania, Philadelphia, PA, USA
    Neuropsychology 26:368-84. 2012
    ..We predicted that comprehension and expression of narrative would be similarly affected and that deficits in both expression and comprehension of narrative would be related to the same anatomic distribution of prefrontal disease...
  24. pmc Patient-physician communication about complementary and alternative medicine in a radiation oncology setting
    Jin Ge
    Perelman School of Medicine at the University of Pennsylvania, Department of Radiation Oncology, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
    Int J Radiat Oncol Biol Phys 85:e1-6. 2013
    ..This study quantified the extent of patient-physician communication about CAM and identified factors associated with its discussion in radiation therapy (RT) settings...
  25. pmc Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
    Sunil Patel
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Fluids Barriers CNS 9:7. 2012
    ..abstract:..
  26. pmc Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology
    Roy Hamilton
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Ann Neurol 68:535-40. 2010
    ....
  27. ncbi request reprint Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication?
    Karen B Hirschman
    Division of Biobehavioral and Health Sciences, The Univ of Pennsylvania, School of Nursing, Philadelphia, PA, USA
    Am J Geriatr Psychiatry 13:1014-21. 2005
    ....
  28. pmc Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy
    Felix Geser
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Alzheimer s Disease Core Center, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 121:509-17. 2011
    ....
  29. pmc Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness
    Felix Geser
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Arch Neurol 67:1238-50. 2010
    ....
  30. pmc Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale
    Sharon X Xie
    Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104 6021, USA
    Alzheimer Dis Assoc Disord 23:268-74. 2009
    ..To measure clinically relevant change in Alzheimer disease (AD) using a family member-completed Dementia Severity Rating Scale (DSRS) questionnaire...
  31. pmc Uncovering the expectancy effect: the validation of the acupuncture expectancy scale
    Jun J Mao
    Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, Center for Clinical Epidemiology and Biostatistics, Philadelphia, USA
    Altern Ther Health Med 16:22-7. 2010
    ..We sought to validate a previously developed Acupuncture Expectancy Scale (AES) as an instrument to measure patients' expected responses to acupuncture...
  32. pmc Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease
    Randolph Stephenson
    Department of Neurology, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA
    Mov Disord 25:2099-104. 2010
    ..These findings suggest that severity of olfactory impairment early in the disease course may be a useful marker for the risk of neuropsychiatric complications of PD...
  33. pmc Design of comprehensive Alzheimer's disease centers to address unmet national needs
    John Q Trojanowski
    Institute on Aging, Philadelphia, PA, USA
    Alzheimers Dement 6:150-5. 2010
    ..The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders...
  34. ncbi request reprint How do patients with Alzheimer disease rate their overall quality of life?
    Bryan D James
    Department of Medicine, Institute on Aging, 3615 Chestnut Street, Philadelphia, PA 19104, USA
    Am J Geriatr Psychiatry 13:484-90. 2005
    ..The authors asked how Alzheimer disease (AD) patients assess their overall quality of life (QOL) and sought to determine the characteristics associated with this assessment...
  35. ncbi request reprint Do Alzheimer's disease patients want to participate in a treatment decision, and would their caregivers let them?
    Karen B Hirschman
    Institute on Aging, 3615 Chestnut Street, Philadelphia, PA 19104, USA
    Gerontologist 45:381-8. 2005
    ....
  36. doi request reprint A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use
    Jun J Mao
    Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, PA, United States Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, PA, United States Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, PA, United States Electronic address
    Eur J Cancer 50:267-76. 2014
    ..Arthralgia is a common and debilitating side-effect experienced by breast cancer patients receiving aromatase inhibitors (AIs) and often results in premature drug discontinuation...
  37. ncbi request reprint Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
    Hanae Nakashima-Yasuda
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP Maloney 3rd Floor, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 114:221-9. 2007
    ..This study expands the concept of TDP-43 proteinopathies by implicating TDP-43 lesions in mechanisms of neurodegeneration in LB disorders...
  38. pmc Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease
    Mark Yarchoan
    Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States
    J Neurol Sci 333:9-12. 2013
    ..Our results support previous reports of reduced levels of plasma CRP in AD and indicate its potential utility as a biomarker for the diagnosis of AD. ..
  39. pmc Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104 2676, USA
    Mov Disord 27:242-7. 2012
    ..Preliminary results suggest that it can be used to support a diagnosis of these disorders, as well as to monitor changes in symptom severity over time...
  40. doi request reprint The heterogeneity of mild cognitive impairment: a neuropsychological analysis
    David J Libon
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    J Int Neuropsychol Soc 16:84-93. 2010
    ..In summary, multi-domain MCI is quite common. These data suggest that MCI is a highly nuanced and complex clinical entity...
  41. pmc Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease
    J Nicholas Lukens
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    Alzheimers Dement 5:463-9. 2009
    ..We examined the correlation between PBL and cerebellum telomere length in AD patients, and compared telomere lengths in cerebella from individuals with AD versus age-matched control subjects...
  42. ncbi request reprint The development of a rapid screen for caregiver burden
    Karen B Hirschman
    School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Am Geriatr Soc 52:1724-9. 2004
    ..To develop a shortened screen for burden associated with caring for a patient with Alzheimer's disease (AD)...
  43. ncbi request reprint Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial
    Gregory K Brown
    Department of Psychiatry, University of Pennsylvania, Philadelphia 19104, USA
    JAMA 294:563-70. 2005
    ..Suicide attempts constitute a major risk factor for completed suicide, yet few interventions specifically designed to prevent suicide attempts have been evaluated...
  44. pmc Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
    Kannie Chim
    Department of Family Medicine and Community Health, University of Pennsylvania, 3400 Spruce Street 2 Gates, Philadelphia, Pennsylvania 19104, USA
    BMC Cancer 13:401. 2013
    ..Premature discontinuation of aromatase inhibitors (AIs) in breast cancer survivors compromises treatment outcomes. We aimed to evaluate whether patient-reported joint pain predicts premature discontinuation of AIs...
  45. pmc Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA
    Acta Neuropathol 126:659-70. 2013
    ....
  46. pmc Differential longitudinal decline on the mini-mental state examination in frontotemporal lobar degeneration and Alzheimer disease
    Kay See Tan
    Departments of Biostatistics and Epidemiology Neurology, Perelman School of Medicine, University of Pennsylvania Department of Neurology, Drexel University College of Medicine, Philadelphia, PA
    Alzheimer Dis Assoc Disord 27:310-5. 2013
    ..To examine how phenotype affects longitudinal decline on the Mini-Mental State Examination (MMSE) in patients with frontotemporal lobar degeneration (FTLD) and Alzheimer disease (AD)...
  47. doi request reprint Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging
    David R Roalf
    Department of Psychiatry, Neuropsychiatry, University of Pennsylvania, Philadelphia, PA, USA
    Alzheimers Dement 9:529-37. 2013
    ....
  48. pmc Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP, Maloney 3rd JQT or 7th LMS Floor, 36th and Spruce Streets, Philadelphia, PA, 19104 4283, USA
    Acta Neuropathol 122:401-13. 2011
    ..Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ...
  49. doi request reprint Predictors of emergent feeding tubes and tracheostomies in amyotrophic lateral sclerosis (ALS)
    Amy Y Tsou
    Robert Wood Johnson Foundation Veterans Affairs Clinical Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Amyotroph Lateral Scler 13:318-25. 2012
    ..Academic hospital affiliation decreased odds of emergent gastrostomy or tracheostomy. After Medicare changes broadening access, while gastrostomy use increased, the proportion of emergent procedures decreased...
  50. pmc Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases
    Sriram Venneti
    Division of Neuropathology, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 122:737-45. 2011
    ....
  51. pmc Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest
    Dana Clay Falcone
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Genet Couns 20:384-95. 2011
    ..Genetic education and counseling tools to address these needs were developed to provide patients with the ability to make informed and knowledgeable genetic testing decisions...
  52. ncbi request reprint Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease
    Andrew Siderowf
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA
    Mov Disord 21:746-53. 2006
    ..01). In this selected group of patients, many of the short-term gains in HRQL persist beyond 18 months after STN implantation. Benefits in nonmotor aspects of HRQL such as bodily discomfort and stigma appear to be among the most durable...
  53. pmc Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy
    Kurt R Brunden
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 30:13861-6. 2010
    ..These results suggest that certain brain-penetrant MT-stabilizing agents might provide a viable therapeutic strategy for the treatment of AD and FTDs...
  54. doi request reprint Development of and psychometric testing for the Brief Pain Inventory-Facial in patients with facial pain syndromes
    John Y K Lee
    Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania 19107, USA
    J Neurosurg 113:516-23. 2010
    ..The complete 18-item instrument is referred to as the BPI-Facial...
  55. pmc Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors
    James J Mao
    Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
    Integr Cancer Ther 8:123-9. 2009
    ..Given the existing evidence for electroacupuncture (EA) for treatment of osteoarthritis in the general population, this study aims to establish the feasibility of studying EA for treating AI-related arthralgia...
  56. pmc Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model
    Bin Zhang
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 102:227-31. 2005
    ..Thus, MT-stabilizing drugs could have therapeutic potential for treating neurodegenerative tauopathies by offsetting losses of tau function that result from the sequestration of this MT-stabilizing protein into filamentous inclusions...
  57. ncbi request reprint Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam
    Felix Geser
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Alzheimer s Disease Core Center, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104 4283, USA
    Acta Neuropathol 115:133-45. 2008
    ..Finally, we conclude that the spectrum of TDP-43 proteinopathies should be expanded to include neurodegenerative cognitive and motor diseases, affecting the Chamorro population of Guam...
  58. pmc Prenatal healthcare providers' Gaucher disease carrier screening practices
    Dana Falcone
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Genet Med 14:844-51. 2012
    ..Gaucher disease carrier screening is controversial in the medical community. The goal of this study was to explore current Gaucher disease carrier screening practices of prenatal healthcare providers...
  59. pmc Development and Validation of an Instrument for Measuring Attitudes and Beliefs about Complementary and Alternative Medicine (CAM) Use among Cancer Patients
    Jun J Mao
    Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, PA 19104, USA
    Evid Based Complement Alternat Med 2012:798098. 2012
    ..001) than those who did not use CAM. Our study provides the initial evidence that the ABCAM instrument produced reliable and valid scores that measured attitudes and beliefs related to CAM use among cancer patients...
  60. ncbi request reprint Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancer
    Jun J Mao
    Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, 2 Gates Building 3400 Spruce Street, Philadelphia, PA 19104, USA
    Complement Ther Med 15:21-9. 2007
    ..Extensive use of complementary and alternative medicine (CAM) among cancer survivors has been described in literature, but the rate has not previously been compared to other groups in a true population sample...
  61. pmc Longitudinal reproducibility and accuracy of pseudo-continuous arterial spin-labeled perfusion MR imaging in typically developing children
    Varsha Jain
    Department of Radiology and Biostatistics, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Radiology 263:527-36. 2012
    ..To evaluate the longitudinal repeatability and accuracy of cerebral blood flow (CBF) measurements by using pseudo-continuous arterial spin-labeled (pCASL) perfusion magnetic resonance (MR) imaging in typically developing children...
  62. pmc Risk factors for death of patients with cystic fibrosis awaiting lung transplantation
    Richard A Belkin
    Division of Pulmonary, Allergy, and Critical Care, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Am J Respir Crit Care Med 173:659-66. 2006
    ..The optimal timing for listing of cystic fibrosis patients for lung transplantation is controversial...
  63. ncbi request reprint How does an Alzheimer's disease patient's role in medical decision making change over time?
    Karen B Hirschman
    Department of Medicine, School of Social Work, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, PA 19104, USA
    J Geriatr Psychiatry Neurol 17:55-60. 2004
    ..These results provide clinicians with prognostic information that can help caregivers understand how their role in decision making will change over the course of a patient's dementing illness...